Skip Navigation

European Journal of Heart Failure 2006 8(7):712-715; doi:10.1016/j.ejheart.2006.03.006
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bayrak, F.
Right arrow Articles by Erginel-Unaltuna, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bayrak, F.
Right arrow Articles by Erginel-Unaltuna, N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society of Cardiology

Ventricular pre-excitation and cardiac hypertrophy mimicking hypertrophic cardiomyopathy in a Turkish family with a novel PRKAG2 mutation

Fatih Bayraka,*, Evrim Komurcu-Bayrakb, Bulent Mutlua, Gokhan Kahvecia, Yelda Basarana and Nihan Erginel-Unaltunab

a Kosuyolu Heart and Research Hospital, Department of Cardiology, Istanbul, Turkey
b Istanbul University, Institute for Experimental Medical Research, Department of Genetics, Istanbul, Turkey

* Corresponding author. Yeditepe University Hospital, Department of Cardiology, Devlet Yolu Ankara Cad. No:102/104, Kozyatagi, Istanbul, Turkey. Tel.: +90 216 5784240; fax: +90 216 4693796. E-mail address: fbayrak{at}yeditepe.edu.tr (F.Bayrak).


   Abstract

Background: Mutations in PRKAG2, the gene for the {gamma}2 regulatory subunit of AMP-activated protein kinase, cause cardiac hypertrophy and electrophysiological abnormalities. We identified a novel mutation in PRKAG2 causing familial ventricular pre-excitation and severe cardiac hypertrophy.

Methods and results: We studied 30 members of one family and 120 healthy controls. Molecular analysis of PRKAG2 gene revealed one missense mutation in exon 14 which was confirmed by restriction enzyme digestion. We identified a G to A transition, resulting in a Glu506Lys substitution in the PRKAG2 gene in 8 of the family members, who all had cardiac hypertrophy and ventricular pre-excitation. High incidence of right ventricular hypertrophy and left ventricular outflow tract obstruction are other prominent features of this novel PRKAG2 mutation. Family members without mutation had no cardiac disease. The 120 unrelated healthy individuals did not show this mutation.

Conclusions: Coexistence of unexplained ventricular hypertrophy and pre-excitation should prompt the diagnosis of PRKAG2 mutations and these patients should be referred for genetic analysis. The possible alteration of AMP-activated protein kinase activity due to genetic defects in PRKAG2 may serve as a template for developing more specific therapies in the treatment of patients with this mutation.

Key Words: Cardiomyopathy • Ventricular pre-excitation • Genetics

Received November 4, 2005; Revised January 19, 2006; Accepted March 27, 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Circ. Res.Home page
M. Arad, C. E. Seidman, and J.G. Seidman
AMP-Activated Protein Kinase in the Heart: Role During Health and Disease
Circ. Res., March 2, 2007; 100(4): 474 - 488.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.